Arcturus Therapeutics Holdings (ARCT) Total Current Liabilities (2018 - 2026)

Arcturus Therapeutics Holdings' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $34.4 million for Q1 2026.

• Quarterly Total Current Liabilities fell 30.44% year-over-year to $34.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.4 million (down 30.44% YoY) and the FY2025 annual result came in at $36.4 million, down 44.45% from the prior year.
• Total Current Liabilities was $34.4 million for Q1 2026 at Arcturus Therapeutics Holdings, down from $36.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $127.0 million in Q4 2022 and bottomed at $31.7 million in Q3 2025.
• A 5-year average of $76.1 million and a median of $82.0 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 101.2% — and 2025, when it sank 57.2%.
• Arcturus Therapeutics Holdings' Total Current Liabilities stood at $127.0 million in 2022, then tumbled by 35.43% to $82.0 million in 2023, then declined by 20.12% to $65.5 million in 2024, then slumped by 44.45% to $36.4 million in 2025, then decreased by 5.53% to $34.4 million in 2026.
• Business Quant data shows ARCT's Total Current Liabilities at $34.4 million in Q1 2026, $36.4 million in Q4 2025, and $31.7 million in Q3 2025.